Genmab Janssen Agreement

Genmab is a publicly traded international biotechnology company specializing in the development and development of differentiated human antibody therapists for the treatment of cancer. The company`s first commercially marketed antibody, ofatumumab (Arzerra), created in 1999, was approved after less than 8 years of development for the treatment of chronic lymphocytic leukemia in patients with fludarabine and alemtuzumab. Partnering with innovative product candidates and technologies is a priority of Genmab`s strategy and the company has forged alliances with leading pharmaceutical and biotechnology companies. For more information, see www.genmab.com. About Genmab Genmab is a publicly traded international biotechnology company specializing in the development and development of differentiated antibody therapy drugs for the treatment of cancer. The company founded in 1999 has two authorized antibodies, DARZALEX® (daratumumab) for the treatment of certain indications of multiple myeloma and Arzerra® (ofatumumab) in the treatment of certain chronic indications of lymphocytic leukemia. Daratumumab is in clinical development for other indications of multiple myeloma, other blood cancers and amylosis. A subcutaneous formulation of ofatumumab is in development for multiple sclerosis. Genmab also has a large pipeline of clinical and preclinical products.

Genmab`s technology base consists of validated and proprietary next-generation antibody technologies – the DuoBody platform® for the production of bi-specific antibodies, the HexaBody® platform, which produces effective antibodies, and the HexElect® platform, which combines two co-dependent hexabody molecules to introduce selectivity while maximizing the The company intends to use these technologies to create opportunities for all or co-ownership of future products. Genmab maintains alliances with leading pharmaceutical and biotechnology companies. For more information, see www.genmab.com. Copenhagen, Denmark; September 22, 2020 – Genmab A/S (Nasdaq: GMAB) today announced that it has commenced firm arbitration proceedings on two issues arising from its licensing agreement with Janssen Biotech, Inc. (Janssen) regarding daratumab. As part of the licensing agreement, Genmab is entitled to Janssen royalties for the sale of daratumumab (marketed as DARZALEX® for intravenous administration and in the United States as DARZALEX FASPRO™ for subcutaneous administration). In a brief statement, Genmab said it initiated mandatory conciliation in connection with two cases as part of its Darzalex (daratumumab) licensing agreement with Janssen Biotech, a subsidiary of the life-sciences giant Johnson and Johnson. Genmab said it is entitled to royalties from the marketing of the drug for the intravenous form of Darzalex, and Darzalex Faspro for subcutaneous administration. Darzalex was the largest cash-cow for the Danish company. “We are very excited to make a new innovation with Janssen and look forward to working with them to accelerate the development of daratumumab and maximize the value of this product,” said Jan van de Winkel, PhD, Chief Executive Officer of Genmab. “This agreement significantly strengthens our financial position and allows Genmab to continue to develop much-needed differentiated antibody drugs to help cancer patients.” “With this agreement, we hope to build on the fruitful and productive relationship we have established with Janssen.

As a result of our collaboration, DARZALEX has significantly improved outcomes for patients with multiple myeloma, but there are still unmet needs for patients.

Comments are closed.